Appendix 4C and Quarterly Business Update December 2022
Filed with ASX · · 9 pages · English
Melbourne, Australia, 30 January 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Appendix 4C and Quarterly business update for the quarter ended 31 December 2022 (Q2 FY23). Highlights: • Qtr 2 Receipts from customers were A$2.4 million, up 15% compared to prior
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- Colorectal Cancer Model Presented at ASCOGI Cancer Symposium
- GeneType Published in PLUS ONE for CVD & Type 2 Diabetes
- AGM Presentation and Chairmans Address
- Genetype for Ovarian Cancer published in European Journal
- GeneType Outperforms Traditional Risk Assessments
Later from Genetic Technologies
- GTG to form Strategic Alliance with global leader QIAGEN
- World First Comprehensive Risk Test-Breast & Ovarian Cancer
- Genetic Technologies Announces US$5M Registered Direct Offer
- Supplementary Announcement - Comprehensive Risk Test
- Business Update - February 2023
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies